Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Diagnostic and Prognostic Implications of AAGAB Expression in Human Breast Cancer

Yong Liu, Cheng Zhang, Wenzhao Cao, Chen Gong, Dan Yin

Background: Alpha and Gamma Adaptin Binding protein p34 (AAGAB) was previously reported as a novel on- treatment biomarker can improve prediction of response to neoadjuvant chemotherapy in breast cancer. However, the expression and prognostic value of AAGAB in breast cancer is unknown, the function of AAGAB remains to be elucidated

Methods: Herein we investigated the role of AAGAB in human breast cancer from the GEO and TCGA databases, immunohistochemistry, Gene Set Enrichment Analysis (GSEA) and immune infiltration analysis

Results: The expression of AAGAB in breast cancer was significantly up-regulated relative to normal tissue (all p-values<0.05) in GEO and TCGA databases. Kaplan-Meier survival analysis showed that breast cancer patients with AAGAB-high had a worse prognosis than that with AAGAB-low (p=0.005). Univariate analysis using logistic regression revealed that age, pathological stage, and number of lymph nodes were significantly associated with poor Overall Survival (OS) (all p<0.05). Functional annotations indicated that AAGAB is involved in the most significant signaling pathways including intra Golgi traffic and peroxisomal lipid metabolism pathways.

Conclusions: Our study revealed that elevated AAGAB expression was significantly correlated with aggressive progression, poor survival in patients. AAGAB may serve as a new biomarker and potential treatment target in breast cancer.